ACCORD COPD II: A randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients

Clinical Drug Investigation

Volumn 33, Issue 12, 2013, Pages 893-904

  Rennard, Stephen I ^a   Scanlon, Paul D ^b   Ferguson, Gary T ^c   Rekeda, Ludmyla ^d   Maurer, Brian T ^d   Garcia Gil, Esther ^e   Caracta, Cynthia F ^d  

^a Division of Pulmonary   (United States)

^b MAYO CLINIC   (United States)

^c Pulmonary Research Institute of Southeast Michigan   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e Almirall SA ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; GENUAIR; PLACEBO; PRESSAIR; SALBUTAMOL; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRADYCARDIA; BRONCHODILATATION; BRONCHOSPASM; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY POWDER INHALER; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HOLTER MONITORING; HUMAN; HYPERTENSION; INSPIRATORY CAPACITY; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; SIDE EFFECT; SINUSITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TACHYCARDIA; TRANSITIONAL BLINDNESS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TROPANES;

EID: 84890299585     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0138-1     Document Type: Article

References (26)

1. World Health Organization (WHO). The global burden of disease: 2004 update. http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-full.pdf. Accessed 21 Dec 2011.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
3. DiBonaventura M, Paulose-Ram R, Su J, et al. The impact of COPD on quality of life, productivity loss, and resource use among the elderly United States workforce. COPD. 2012;9(1):46-57.
4. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65.
5. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984;311(7):421-5.
6. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010;39(5):283-90.
7. Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90-101.
8. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-6.
9. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-9.
10. Mahler DA, Witek TJ Jr. The MCID of the Transition Dyspnea Index is a total score of one unit. COPD. 2005;2(1):99-103.
11. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111-24.
12. Koch GG, Amara IA, Davis GW, et al. A review of some statistical methods for covariance analysis of categorical data. Biometrics. 1982;38(3):563-95.
13. Koch GG, Gillings DB, Stokes ME. Biostatistical implications of design, sampling, and measurement to health science data analysis. Annu Rev Public Health. 1980;1:163-225.
14. Koch GG, Tangen CM, Jung JW, et al. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med. 1998;17(15-16):1863-92.
15. Miratrix LW, Sekhon JS, Yu B. Adjusting treatment effect estimates by post-stratification in randomized experiments. 2012. http://sekhon.berkeley.edu/ papers/postadjustment.pdf. Accessed 3 Apr 2012.
16. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-69.
17. Mahler DA, Tomlinson D, Olmstead EM, et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med. 1995;151(1):61-5.
18. Hajiro T, Nishimura K, Tsukino M, et al. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest. 1999;116(6):1632-7.
19. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267-72.
20. Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet. 2007;370(9589):774-85.
21. Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
22. O'Donnell DE, Guenette JA, Maltais F, et al. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest. 2012;141(3):753-62.
23. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J. 2012;40(2):322-9.
24. Hannink JD, van Helvoort HA, Dekhuijzen PN, et al. Dynamic hyperinflation during daily activities: does COPD Global Initiative for Chronic Obstructive Lung Disease stage matter? Chest. 2010;137(5):1116-21.
25. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 microgram twice daily compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest. 2012;141(3):745-52.
26. Singh D, Magnussen H, Kirsten A, et al. A randomised placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25(3):248-53.